These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 1503686)

  • 1. Natural history of advanced HIV disease in patients treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Moore RD; Keruly J; Richman DD; Creagh-Kirk T; Chaisson RE
    AIDS; 1992 Jul; 6(7):671-7. PubMed ID: 1503686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
    Gallant JE; Moore RD; Richman DD; Keruly J; Chaisson RE
    Arch Intern Med; 1994 Mar; 154(5):566-72. PubMed ID: 8122950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group.
    Moore RD; Creagh-Kirk T; Keruly J; Link G; Wang MC; Richman D; Chaisson RE
    Arch Intern Med; 1991 May; 151(5):981-6. PubMed ID: 1673837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of patients receiving zidovudine before or after AIDS diagnosis: results of a German multicenter study. German AIDS Study Group.
    Clin Investig; 1994 Jan; 72(2):111-6. PubMed ID: 8186655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.
    Spector SA; Gelber RD; McGrath N; Wara D; Barzilai A; Abrams E; Bryson YJ; Dankner WM; Livingston RA; Connor EM
    N Engl J Med; 1994 Nov; 331(18):1181-7. PubMed ID: 7935655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
    Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
    Vial PA; Ferreccio C; Abarca K; Ortiz E; Noriega M; Pérez C; Labarca J; Torres M; Ferrés M; González C; Acuña G
    Rev Med Chil; 1996 May; 124(5):525-35. PubMed ID: 9035503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender-specific differences in the natural history, clinical features, and socioeconomic status of HIV-infected patients: experience of a treatment centre in Vienna.
    Armbruster C; Kriwanek S; Vorbach H
    Wien Klin Wochenschr; 2000 Sep; 112(17):754-60. PubMed ID: 11042904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of monitored CD4 cell counts: predictions of the AIDS epidemic in Scotland: CD4 Collaborative Group.
    AIDS; 1992 Feb; 6(2):213-22. PubMed ID: 1348418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group.
    Schwartländer B; Bek B; Skarabis H; Koch J; Burkowitz J; Koch MA
    AIDS; 1993 Jun; 7(6):813-21. PubMed ID: 8103341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival without clinical AIDS after CD4+ cell counts fall below 200 x 10(6)/l.
    Hoover DR; Rinaldo C; He Y; Phair J; Fahey J; Graham NM
    AIDS; 1995 Feb; 9(2):145-52. PubMed ID: 7718184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of CD4 cell decline and prediction of survival in zidovudine-treated patients.
    Easterbrook PJ; Emami J; Gazzard B
    AIDS; 1993 Oct; 7(10):959-67. PubMed ID: 7903542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progression to AIDS among HIV-seropositive hemophiliacs].
    Lorenzo JI; Molina R; Senent ML; Monzó E; Lerma MA; Dasí MA; Monteagudo E; Aznar JA
    Sangre (Barc); 1992 Jun; 37(3):169-74. PubMed ID: 1440093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.
    McKinney RE; Maha MA; Connor EM; Feinberg J; Scott GB; Wulfsohn M; McIntosh K; Borkowsky W; Modlin JF; Weintrub P
    N Engl J Med; 1991 Apr; 324(15):1018-25. PubMed ID: 1672443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS).
    Farinpour R; Miller EN; Satz P; Selnes OA; Cohen BA; Becker JT; Skolasky RL; Visscher BR
    J Clin Exp Neuropsychol; 2003 Aug; 25(5):654-70. PubMed ID: 12815503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zidovudine and the natural history of the acquired immunodeficiency syndrome.
    Moore RD; Hidalgo J; Sugland BW; Chaisson RE
    N Engl J Med; 1991 May; 324(20):1412-6. PubMed ID: 2020297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hodgkin's disease associated with HIV infection: clinical characteristics and development. French registry of tumors associated with HIV infection].
    Roithmann S; Tourani JM; Gastaut JA; Brice P; Raphaël M; Dujardin P; Desablens B; Andrieu JM
    Bull Cancer; 1992; 79(9):873-82. PubMed ID: 1486223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.